Takeda Pharmaceutical said on August 22 that its live-attenuated tetravalent dengue vaccine Qdenga, previously known as TAK-003, has won its first approval in the world in Indonesia. It is the company’s first jab marketed outside of Japan. The Indonesia National…
To read the full story
Related Article
- Takeda’s Dengue Vaccine Proves 4.5-Year Protection
June 10, 2022
BUSINESS
- Lunsumio Combo Hits PIII Goal in Follicular Lymphoma: Roche
September 18, 2026
- Padcev-Keytruda Gets CHMP Nod for Expanded MIBC Use
September 18, 2026
- SanBio Eyes October Start for Akuugo Treatment
September 18, 2026
- Toho Unit to Launch Pharma-Wholesaler Payment Service
September 18, 2026
- Astellas Names Marino General Counsel, Compliance Chief
September 18, 2026
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…





